State-of-the-art centre to focus on digital and robotic surgery
LONDON, Nov. 10, 2021 /PRNewswire/ — Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces its first dedicated Medical Education Centre to support customers across the Asia Pacific region.
Strategically located in Singapore, the centre will support the safe and effective use of Smith+Nephew’s products as well as the professional development of healthcare professionals across the region. It is expected to be operational by mid-2022.
The centre will have a strong focus on digital and robotic surgery, featuring Smith+Nephew’s Real Intelligence ecosystem of products, as well as supporting training across all product portfolios which include orthopaedic reconstruction, sports medicine, ear, nose and throat and advanced wound management.
Healthcare professionals will benefit from digital training technology including interactive LED displays, augmented and virtual reality, and the experience of hands-on digital operating rooms. A specially designed digital app will integrate all aspects of the learning journey including enabling attendees to design their own agenda, register for upcoming events, perform contactless check-in, book virtual or augmented reality sessions, and access training modules on Smith+Nephew’s learning management system, Education Unlimited.
Smith+Nephew APAC President, Myra Eskes commented, “We are thrilled to establish a world class training centre in the region which will encompass a seamless end-to-end learning journey for our healthcare professional customers from across the Asia-Pacific region. Aligned to our Company purpose and strategic business objectives, this next-generation centre will be pivotal in delivering engaging, immersive and interactive training as well as driving our business forward.”
Supporting Smith+Nephew’s purpose of Life Unlimited, the Medical Education Centre together with the app and Education Unlimited aim to enhance the learning journey of healthcare professionals to achieve the best patient outcomes. The new facility in Singapore is the latest addition to Smith+Nephew’s global network which includes owned centres in Europe and the US.
Smith+Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $4.6 billion in 2020. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.
™ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.
The content is by PR NewsWire. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.